Company / Current Liabilities
Neurocrine Biosciences Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$743.4M
FY2025
5-year range
$245.8M / $743.4M
FY2021-FY2025
Trend
+46.4%
vs FY2024
Sector context
#31 of 215
Health Care
What the data says
Neurocrine Biosciences's current liabilities of $743M is higher than 86% of companies in the Health Care sector (FY2025). Current Liabilities has fluctuated over the past 10 years, ranging from $30M in FY2016 to $743M in FY2025.
Based on SEC 10-K filings.
$743M in FY2025 with a 5-year CAGR of +31.9%. Top quartile in the Health Care sector.
Increased from $655M to $743M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +11.4%
- 5-Year CAGR
- +31.9%
- 10-Year CAGR
- -
Sector benchmark
-52.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +31.9%, indicating consistent growth.
- In FY2025, current liabilities increased 46.4% year-over-year.
- Ranks #31 out of 215 companies in the Health Care sector.
- Lowest current liabilities in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $743.4M | +46.4% |
| FY2024 | $507.7M | -22.5% |
| FY2023 | $654.8M | +21.8% |
| FY2022 | $537.7M | +118.8% |
| FY2021 | $245.8M | +31.8% |
| FY2020 | $186.5M | -67.0% |
| FY2019 | $565.3M | +540.7% |
| FY2018 | $88.2M | +62.1% |
| FY2017 | $54.4M | +79.0% |
| FY2016 | $30.4M | +18.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026